Quell Therapeutics makes FierceBiotech’s 2019 Fierce 15

The list highlights biotech companies whose hard work and cutting-edge research aims to stop disease in its tracks.

Formed earlier this year, UCLTF portfolio company, Quell Thereapeutics was established with the aim of developing engineered T regulatory (Treg) cell therapies. Bringing together leaders in this field of expertise, Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases.

Find out more: FierceBiotech & UCLTF.

Related Content

We make UCL’s research physical and life sciences ideas happen.